Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 5/20 | 0.52 |
| ▸ | CTSS | P25774 | 2/20 | 0.47 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.38 |
| ▸ | KLK7 | P49862 | 1/20 | 0.38 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20211104 | 0.90 | CTSK (0.54) | CTSKCTSSJAK3BTKMAPT | |
| SCHEMBL31277610 | 0.90 | CTSK (0.54) | CTSKCTSSJAK3BTKMAPT | |
| SCHEMBL16762094 | 0.90 | CTSK (0.54) | CTSKCTSSJAK3BTKMAPT | |
| SCHEMBL6122352 | 0.90 | CTSK (0.54) | CTSKCTSSJAK3BTKMAPT | |
| SCHEMBL23357781 | 0.88 | CTSK (0.52) | CTSKCTSSJAK3BTKCTSL | |
| SCHEMBL8828162 | 0.88 | CTSK (0.52) | CTSKCTSSJAK3BTKCTSL | |
| SCHEMBL31277249 | 0.87 | CTSK (0.52) | CTSKCTSSJAK3BTKCTSL | |
| SCHEMBL16762218 | 0.87 | CTSK (0.55) | CTSKCTSSJAK3BTKCTSL | |
| SCHEMBL16762156 | 0.87 | FOLH1 (0.41) | MAPTMEN1KMT2A | |
| SCHEMBL21715249 | 0.86 | CTSK (0.48) | CTSKCTSSJAK3BTKCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240189360-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE HOMING AND GRAFTING OF HEMATOPOETIC STEM CELLS | 7 HILLS PHARMA INC. (US) | 2024-06-13 | — | — | US | disclosed |
| US-11311619-B2 | Integrin activator vaccine compositions | 7 Hills Pharma Inc. and Texas Heart Institute (US) | 2022-04-26 | — | — | US | disclosed |
| EP-3104867-B1 | COMPOSITIONS AND METHODS TO IMPROVE THE HOMING AND GRAFTING OF HEMATOPOETIC STEM CELLS | 7 Hills Pharma LLC (US) | 2022-01-19 | — | — | EP | disclosed |
| US-20210023207-A1 | NOVEL INTEGRIN ACTIVATOR VACCINE COMPOSITIONS | 7 Hills Pharma LLC (US) | 2021-01-28 | — | — | US | disclosed |
| US-10716849-B2 | Methods of administering novel integrin activator vaccine compositions | 7 Hills Pharma LLC (US) | 2020-07-21 | — | — | US | disclosed |
| US-10709781-B2 | Integrin activator checkpoint inhibitor compositions | 7 Hills Pharma LLC (US) | 2020-07-14 | — | — | US | disclosed |
| US-20200054743-A1 | NOVEL INTEGRIN ACTIVATOR CHECKPOINT INHIBITOR COMPOSITIONS | 7 Hills Pharma LLC (US) | 2020-02-20 | — | — | US | disclosed |
| US-20190343952-A1 | METHODS OF ADMINISTERING NOVEL INTEGRIN ACTIVATOR VACCINE COMPOSITIONS | 7 Hills Pharma LLC (US) | 2019-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11311619-B2 | Integrin activator vaccine compositions | ITGAM, ITGA2B, ITGA1 | CTSK 1937/4885CTSS 2200/4885JAK3 3756/4885 |
| US-20200054743-A1 | NOVEL INTEGRIN ACTIVATOR CHECKPOINT INHIBITOR COMPOSITIONS | CD47, ITGA1, ITGA2B | CTSK 2806/4885CTSS 3023/4885JAK3 2034/4885 |
| US-10709781-B2 | Integrin activator checkpoint inhibitor compositions | CD47, ITGA1, ITGAM | CTSK 2680/4885CTSS 2871/4885JAK3 2238/4885 |
| US-10716849-B2 | Methods of administering novel integrin activator vaccine compositions | ITGAM, ITGA2B, ITGA2 | CTSK 2140/4885CTSS 1780/4885JAK3 2814/4885 |
| US-20190343952-A1 | METHODS OF ADMINISTERING NOVEL INTEGRIN ACTIVATOR VACCINE COMPOSITIONS | ITGAM, ITGA2B, ITGA2 | CTSK 2140/4885CTSS 1780/4885JAK3 2814/4885 |
| US-20210023207-A1 | NOVEL INTEGRIN ACTIVATOR VACCINE COMPOSITIONS | ITGA2B, ITGAM, ITGAV | CTSK 1565/4885CTSS 1516/4885JAK3 3715/4885 |
| US-20240189360-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE HOMING AND GRAFTING OF HEMATOPOETIC STEM CELLS | CXCL12, ITGB3, ITGB7 | CTSK 3406/4885CTSS 3941/4885JAK3 1250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.